Cargando…
Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC(50) values i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959220/ https://www.ncbi.nlm.nih.gov/pubmed/31937861 http://dx.doi.org/10.1038/s41598-019-57155-7 |
_version_ | 1783487548687908864 |
---|---|
author | Serda, Maciej Malarz, Katarzyna Mrozek-Wilczkiewicz, Anna Wojtyniak, Marcin Musioł, Robert Curley, Steven A. |
author_facet | Serda, Maciej Malarz, Katarzyna Mrozek-Wilczkiewicz, Anna Wojtyniak, Marcin Musioł, Robert Curley, Steven A. |
author_sort | Serda, Maciej |
collection | PubMed |
description | The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC(50) values in the low micromolar range, with the most active compound at 39 µM. Moreover, we have demonstrated that formation of protein corona on the surface of [60]fullerene derivatives is changing the landscape of their activity, tuning the selectivity of obtained carbon nanomaterials towards Fyn A and BTK kinases. The performed molecular biology studies revealed no cytotoxicity and no influence of engineered carbon nanomaterials on the cell cycle of PANC-1 and AsPC-1 cancer cell lines. Incubation with the tested compounds resulted in the cellular redox imbalance triggering the repair systems and influenced the changing of protein levels. |
format | Online Article Text |
id | pubmed-6959220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69592202020-01-16 Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment Serda, Maciej Malarz, Katarzyna Mrozek-Wilczkiewicz, Anna Wojtyniak, Marcin Musioł, Robert Curley, Steven A. Sci Rep Article The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC(50) values in the low micromolar range, with the most active compound at 39 µM. Moreover, we have demonstrated that formation of protein corona on the surface of [60]fullerene derivatives is changing the landscape of their activity, tuning the selectivity of obtained carbon nanomaterials towards Fyn A and BTK kinases. The performed molecular biology studies revealed no cytotoxicity and no influence of engineered carbon nanomaterials on the cell cycle of PANC-1 and AsPC-1 cancer cell lines. Incubation with the tested compounds resulted in the cellular redox imbalance triggering the repair systems and influenced the changing of protein levels. Nature Publishing Group UK 2020-01-14 /pmc/articles/PMC6959220/ /pubmed/31937861 http://dx.doi.org/10.1038/s41598-019-57155-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Serda, Maciej Malarz, Katarzyna Mrozek-Wilczkiewicz, Anna Wojtyniak, Marcin Musioł, Robert Curley, Steven A. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
title | Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
title_full | Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
title_fullStr | Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
title_full_unstemmed | Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
title_short | Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
title_sort | glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959220/ https://www.ncbi.nlm.nih.gov/pubmed/31937861 http://dx.doi.org/10.1038/s41598-019-57155-7 |
work_keys_str_mv | AT serdamaciej glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment AT malarzkatarzyna glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment AT mrozekwilczkiewiczanna glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment AT wojtyniakmarcin glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment AT musiołrobert glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment AT curleystevena glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment |